Syndax Presents Positive Revuforj® (Revumenib) Data in Acute Leukemias From Multiple Trials, Including the Save Combination and Augment-101 Trials, at 66TH Ash Annual Meeting
Syndax在第66屆ASH年會上展示了多個試驗中急性白血病患者使用Revuforj®（Revumenib）的積極數據，包括Save組合和Augment-101試驗。
